154 related articles for article (PubMed ID: 17433542)
1. Rosuvastatin reduces gliosis and the accelerated weight gain observed in WT and ApoE-/- mice exposed to a high cholesterol diet.
Famer D; Crisby M
Neurosci Lett; 2007 May; 419(1):68-73. PubMed ID: 17433542
[TBL] [Abstract][Full Text] [Related]
2. Rosuvastatin reduces microglia in the brain of wild type and ApoE knockout mice on a high cholesterol diet; implications for prevention of stroke and AD.
Famer D; Wahlund LO; Crisby M
Biochem Biophys Res Commun; 2010 Nov; 402(2):367-72. PubMed ID: 20946880
[TBL] [Abstract][Full Text] [Related]
3. Effects of high cholesterol diet on gliosis in apolipoprotein E knockout mice. Implications for Alzheimer's disease and stroke.
Crisby M; Rahman SM; Sylvén C; Winblad B; Schultzberg M
Neurosci Lett; 2004 Oct; 369(2):87-92. PubMed ID: 15450674
[TBL] [Abstract][Full Text] [Related]
4. High cholesterol diet results in increased expression of interleukin-6 and caspase-1 in the brain of apolipoprotein E knockout and wild type mice.
Rahman SM; Van Dam AM; Schultzberg M; Crisby M
J Neuroimmunol; 2005 Dec; 169(1-2):59-67. PubMed ID: 16198427
[TBL] [Abstract][Full Text] [Related]
5. [Impact of rosuvastatin on atherosclerosis lesions in apolipoprotein E knockout mice].
Luo RN; Tao LJ; Zhou J; Wang R; Lu MM; Fu X
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Aug; 39(8):743-8. PubMed ID: 22169423
[TBL] [Abstract][Full Text] [Related]
6. Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice.
Enomoto S; Sata M; Fukuda D; Nakamura K; Nagai R
Biomed Pharmacother; 2009 Jan; 63(1):19-26. PubMed ID: 18162361
[TBL] [Abstract][Full Text] [Related]
7. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
[TBL] [Abstract][Full Text] [Related]
8. Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice.
Guo H; Shi Y; Liu L; Sun A; Xu F; Chi J
Arch Med Res; 2009 Jul; 40(5):345-51. PubMed ID: 19766896
[TBL] [Abstract][Full Text] [Related]
9. Cardiac hypertrophy during hypercholesterolemia and its amelioration with rosuvastatin and amlodipine.
Kang BY; Wang W; Palade P; Sharma SG; Mehta JL
J Cardiovasc Pharmacol; 2009 Oct; 54(4):327-34. PubMed ID: 19687748
[TBL] [Abstract][Full Text] [Related]
10. Rosuvastatin attenuates monocyte-endothelial cell interactions and vascular free radical production in hypercholesterolemic mice.
Li W; Asagami T; Matsushita H; Lee KH; Tsao PS
J Pharmacol Exp Ther; 2005 May; 313(2):557-62. PubMed ID: 15665143
[TBL] [Abstract][Full Text] [Related]
11. Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo.
Pelat M; Dessy C; Massion P; Desager JP; Feron O; Balligand JL
Circulation; 2003 May; 107(19):2480-6. PubMed ID: 12719275
[TBL] [Abstract][Full Text] [Related]
12. Rosuvastatin selectively stimulates apolipoprotein A-I but not apolipoprotein A-II synthesis in Hep G2 cells.
Qin S; Koga T; Ganji SH; Kamanna VS; Kashyap ML
Metabolism; 2008 Jul; 57(7):973-9. PubMed ID: 18555840
[TBL] [Abstract][Full Text] [Related]
13. Rosuvastatin reduces plasma lipids by inhibiting VLDL production and enhancing hepatobiliary lipid excretion in ApoE*3-leiden mice.
Delsing DJ; Post SM; Groenendijk M; Solaas K; van der Boom H; van Duyvenvoorde W; de Wit EC; Bloks VW; Kuipers F; Havekes LM; Princen HM
J Cardiovasc Pharmacol; 2005 Jan; 45(1):53-60. PubMed ID: 15613980
[TBL] [Abstract][Full Text] [Related]
14. Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice.
Monetti M; Canavesi M; Camera M; Parente R; Paoletti R; Tremoli E; Corsini A; Bellosta S
Pharmacol Res; 2007 May; 55(5):441-9. PubMed ID: 17350858
[TBL] [Abstract][Full Text] [Related]
15. Effect of rosuvastatin on methionine-induced hyperhomocysteinaemia and haematological changes in rats.
Nigam GK; Ansari MN; Bhandari U
Basic Clin Pharmacol Toxicol; 2008 Sep; 103(3):287-92. PubMed ID: 18684217
[TBL] [Abstract][Full Text] [Related]
16. Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet.
Shimizu T; Miura S; Tanigawa H; Kuwano T; Zhang B; Uehara Y; Saku K
Arterioscler Thromb Vasc Biol; 2014 Oct; 34(10):2246-53. PubMed ID: 25104799
[TBL] [Abstract][Full Text] [Related]
17. Rosuvastatin inhibits TIMP-2 and promotes myocardial angiogenesis.
Siddiqui AJ; Gustafsson T; Sylven C; Crisby M
Pharmacology; 2014; 93(3-4):178-84. PubMed ID: 24854110
[TBL] [Abstract][Full Text] [Related]
18. Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice.
Desjardins F; Sekkali B; Verreth W; Pelat M; De Keyzer D; Mertens A; Smith G; Herregods MC; Holvoet P; Balligand JL
Eur Heart J; 2008 Jan; 29(1):128-37. PubMed ID: 18063594
[TBL] [Abstract][Full Text] [Related]
19. Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury.
Schäfer K; Kaiser K; Konstantinides S
Thromb Haemost; 2005 Jan; 93(1):145-52. PubMed ID: 15630505
[TBL] [Abstract][Full Text] [Related]
20. Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia.
Pirro M; Schillaci G; Mannarino MR; Savarese G; Vaudo G; Siepi D; Paltriccia R; Mannarino E
Nutr Metab Cardiovasc Dis; 2007 Jul; 17(6):436-41. PubMed ID: 17134956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
